Eckuity Capital announced the first close of Fund II on June 26, 2026 — extending a healthcare growth equity strategy that is fully deployed across 14 companies in Fund I.

Key facts

• Firm: Eckuity Capital
• Date announced: June 26, 2026
• Fund: Eckuity Capital Fund II (first close)
• Focus: Commercial-stage life sciences — medtech, diagnostics, tech-enabled services
• Geography: North America and Western Europe
• HQ: New York, London, Miami
• Founder: Youssef Sebban (Managing Partner)

Fund II inaugural investment

Led Series C of Automata Technologies alongside Danaher — robotics and lab automation at commercial scale.

New partners added

• Paul Enever — Former McKinsey partner, 25 years in medtech; boards include GT Medical, Magnolia Medical; exit: Cardiva Medical to Haemonetics
• Alejandro Sanchez — Former McKinsey partner, co-founder Hermes Growth Partners; board: PreludeDx; exit: Biotheranostics to Hologic

Why this matters

Eckuity fills a niche between NYC seed life sciences VCs and mega buyout PE — commercial-stage healthcare growth with hands-on operating support. Fund I full deployment across 14 companies validates the model before Fund II scales.

Sources

1. VCWire (June 26, 2026): https://vcwire.tech/2026/06/26/eckuity-capital-holds-first-close-of-fund-ii/